Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... LAGUNA HILLS, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... CA recently became the first hospital on ... site robotic technology. This new surgical option provides women ... Marc Winter , ... gynecologist and surgeon and medical director of minimally ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
(Date:5/23/2013)... BUSAN, South Korea , May 23, 2013 ... collaboration with SillaJen, Inc., a private biotherapeutics and ... of targeted biological products for cancer, announced today ... antibodies in patients treated with the oncolytic and ... This research was published in the ...
(Date:5/23/2013)... May 23, 2013 Watlow®, an ... complete thermal systems, recently introduced its new catalog, ... of experience in designing and manufacturing industrial heaters, ... products to serve diverse customer needs. , A ... at the beginning of the book. These options ...
Breaking Biology Technology:Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2
... Israel, Nov. 29 Protalix,BioTherapeutics, Inc. (Amex: PLX ... the close of business on December 24, 2007, as ... and to vote at, the,Company,s 2007 Annual Meeting of ... Meeting of Shareholders will be held on,January 31, 2008, ...
... the treatment ... disease ... Symbol: RVX, CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... of the very prestigious,Technology Pioneer Award in recognition of its NexVas(TM) Plaque Removal,program. ...
... Jerusalem Global Ventures today,announced that it will soon ... fund. The Fund will invest in private Israeli related,technology ... three years and,have a proven business model. First closing ... who founded Jerusalem Global in 1994, notes that,"Unlike the ...
Cached Biology Technology:Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 2Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 3Resverlogix Honoured with World Economic Forum Technology Pioneer Award 2Resverlogix Honoured with World Economic Forum Technology Pioneer Award 3Resverlogix Honoured with World Economic Forum Technology Pioneer Award 4Resverlogix Honoured with World Economic Forum Technology Pioneer Award 5Jerusalem Global Ventures Announces $200 Million Growth Equity Fund 2
(Date:5/23/2013)... with autologous cord blood. Following a cardiac arrest with ... been in a persistent vegetative state with minimal ... the cord blood containing stem cells, the symptoms improved ... speak simple sentences and to move. "Our findings, along ... doubts about the effectiveness of the new therapy", says ...
(Date:5/22/2013)... NEW YORK CITY, May 22, 2013 U.S. Forest ... multi-disciplinary team that, with funding from the TKF Foundation, ... spaces help communities and individuals recover from tragedy. , ... is one of six projects selected for grant funding. ... spaces and sacred spaces in recovery and resiliency, the ...
(Date:5/22/2013)... 22, 2013)The omega 3 fatty acids in fish oil ... much so that the American Heart Association currently recommends ... particularly fatty varieties rich in omega 3s. However, the ... In a new study, scientists led by Jason R. ... phenomenon by providing evidence that fish oil might specifically ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Fish oil may help the heart beat mental stress 2
... and US scientists has found there has been a massive ... the coast of Antarctica.,Comparing detailed measurements taken during the Australian ... data dating back to 1970, scientists estimate there has been ... volume of Antarctic Bottom Water, the cold dense water that ...
... IMPACT World+, the first worldwide regionalized life cycle impact ... during the 6th SETAC World Congress / SETAC Europe ... this innovative undertaking spearheaded by a team of leading ... production and consumption of goods and services generate significant ...
... able to target and destroy triple negative breast cancer, ... access journal Breast Cancer Research . Researchers from ... was able to destroy breast cancer cells and reduce ... cancers are found at diagnosis to be triple negative. ...
Cached Biology News:Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Launch of IMPACT World+ 2Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2
... CHEMICON APO-BRDU Kit is a ... breaks and total cellular DNA to detect ... kit contains the instructions and reagents required ... and negative control cells for assessing reagent ...
... with temperature probe, 100-120 and 220-240 V, supports ... and 400 W. The temperature probe is used ... degrees C during electrophoresis. Built-in infrared capability allows ... are provided. Dimensions are 27.5 x 34 x ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Criterion staining and blotting trays are plastic trays designed for staining one or two Criterion gels or performing western blot detection. The trays have a working capacity of up to 500 ml. Suppli...
Biology Products: